FI921353A0 - Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris. - Google Patents
Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.Info
- Publication number
- FI921353A0 FI921353A0 FI921353A FI921353A FI921353A0 FI 921353 A0 FI921353 A0 FI 921353A0 FI 921353 A FI921353 A FI 921353A FI 921353 A FI921353 A FI 921353A FI 921353 A0 FI921353 A0 FI 921353A0
- Authority
- FI
- Finland
- Prior art keywords
- pathologies
- beta
- tgf
- vaextfaktor
- transformerande
- Prior art date
Links
- 230000007170 pathology Effects 0.000 abstract 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Coils Or Transformers For Communication (AREA)
- Details Of Television Scanning (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41508189A | 1989-09-29 | 1989-09-29 | |
| US41665689A | 1989-10-03 | 1989-10-03 | |
| PCT/US1990/005566 WO1991004748A1 (fr) | 1989-09-29 | 1990-09-27 | INHIBITION DE FACTEUR β DE CROISSANCE A TRANSFORMATION AFIN D'EMPECHER L'ACCUMULATION DE MATRICE EXTRACELLULAIRE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI921353A FI921353A (fi) | 1992-03-27 |
| FI921353A0 true FI921353A0 (fi) | 1992-03-27 |
Family
ID=27022856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI921353A FI921353A0 (fi) | 1989-09-29 | 1992-03-27 | Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris. |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0494264B1 (fr) |
| JP (1) | JPH0780780B2 (fr) |
| AT (1) | ATE154514T1 (fr) |
| AU (1) | AU654938B2 (fr) |
| CA (1) | CA2065860C (fr) |
| DE (1) | DE69030956T2 (fr) |
| DK (1) | DK0494264T3 (fr) |
| FI (1) | FI921353A0 (fr) |
| NO (1) | NO921119L (fr) |
| WO (1) | WO1991004748A1 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| WO1993010808A1 (fr) * | 1991-12-04 | 1993-06-10 | La Jolla Cancer Research Foundation | INHIBITION DU FACTEUR DE CROISSANCE TRANSFORMATEUR β AFIN DE PREVENIR L'ACCUMULATION DE LA MATRICE EXTRACELLULAIRE |
| GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
| WO1993019783A1 (fr) * | 1992-04-01 | 1993-10-14 | The Whittier Institute For Diabetes And Endocrinology | Procedes permettant d'inhiber ou de stimuler la formation de cicatrices dans le systeme nerveux central |
| US5395825A (en) * | 1993-03-10 | 1995-03-07 | Yale University | Fertility regulation with transforming growth factor β |
| US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| WO1995013827A1 (fr) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | Procede de prevention ou de reduction de la cataracte |
| EP0754058B1 (fr) * | 1994-03-29 | 1999-11-03 | The Victoria University Of Manchester | Cicatrisation |
| CA2221318C (fr) * | 1995-06-02 | 2012-01-24 | Nexstar Pharmaceuticals, Inc. | Ligands oligonucleotidiques ayant une affinite elevee pour les facteurs de croissance |
| GB2304045A (en) † | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
| US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| AU2008200019B2 (en) * | 1999-01-05 | 2009-10-08 | American National Red Cross | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU771635B2 (en) * | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2400628A1 (fr) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Emploi d'antagonistes de tgf-beta dans le traitement ou la prevention de la perte de la fonction renale |
| JP4566605B2 (ja) * | 2004-04-02 | 2010-10-20 | 有限会社開発顧問室 | 短鎖ペプチドを有効成分とするコラーゲン合成阻害剤およびその製造方法 |
| SI2730277T1 (sl) | 2004-12-22 | 2020-07-31 | Nitto Denko Corporation | Nosilec zdravila in komplet za nosilec zdravila za zaviranje fibroze |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| EP1948675B1 (fr) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Methodes et compositions de traitement du syndrome de marfan et de troubles associes |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| US8454952B2 (en) | 2006-03-13 | 2013-06-04 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| EP2083863B1 (fr) | 2006-10-03 | 2015-03-18 | Genzyme Corporation | Anticorps contre le tgf-beta pour l'utilisation dans le traitement des nourrissons risquant de développer une dysplasie broncho-pulmonaire |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| US8956868B2 (en) | 2010-12-27 | 2015-02-17 | Lsip, Llc | Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor |
| ES2894398T3 (es) | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Anticuerpos específicos para TGF-beta |
| WO2013014262A1 (fr) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de diagnostic et de traitement du syndrome de myhre |
| WO2013062544A1 (fr) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cystéamine dans le traitement d'une maladie fibreuse |
| JP6218229B2 (ja) | 2011-12-28 | 2017-10-25 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| JPWO2015064768A1 (ja) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
| EP3127915B1 (fr) | 2014-04-02 | 2020-08-26 | Nitto Denko Corporation | Molécule de ciblage dérivée de rbp et son utilisation |
| CA2943733C (fr) | 2014-04-07 | 2022-03-01 | Nitto Denko Corporation | Hydrotropes a base de polymere pour l'administration de medicament hydrophobe |
| US10092891B2 (en) | 2014-04-25 | 2018-10-09 | University Of Florida Research Foundation, Incorporated | Controlling the activity of growth factors, particularly TGF-β, in vivo |
| US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
| US11246883B2 (en) * | 2016-09-30 | 2022-02-15 | Academia Sinica | Microrna let-7 and transforming growth factor beta receptor III axis as target for cardiac injuries |
| EP3996694A1 (fr) * | 2019-07-31 | 2022-05-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Peptides en tant qu'inhibiteurs de l'accumulation de matrice fibreuse |
| EP3771464A1 (fr) | 2019-07-31 | 2021-02-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Peptides en tant qu'inhibiteurs d'accumulation de matrice fibrogène |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| US5384309A (en) * | 1989-07-17 | 1995-01-24 | Genentech, Inc. | Cyclized peptides and their use as platelet aggregation inhibitors |
-
1990
- 1990-09-27 AT AT90915863T patent/ATE154514T1/de not_active IP Right Cessation
- 1990-09-27 DE DE69030956T patent/DE69030956T2/de not_active Expired - Lifetime
- 1990-09-27 DK DK90915863.6T patent/DK0494264T3/da active
- 1990-09-27 AU AU66125/90A patent/AU654938B2/en not_active Expired
- 1990-09-27 EP EP90915863A patent/EP0494264B1/fr not_active Expired - Lifetime
- 1990-09-27 WO PCT/US1990/005566 patent/WO1991004748A1/fr active IP Right Grant
- 1990-09-27 EP EP96250263A patent/EP0775742A3/fr not_active Withdrawn
- 1990-09-27 JP JP2514972A patent/JPH0780780B2/ja not_active Expired - Fee Related
- 1990-09-27 CA CA002065860A patent/CA2065860C/fr not_active Expired - Lifetime
-
1992
- 1992-03-20 NO NO92921119A patent/NO921119L/no unknown
- 1992-03-27 FI FI921353A patent/FI921353A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO921119D0 (no) | 1992-03-20 |
| NO921119L (no) | 1992-03-20 |
| EP0494264B1 (fr) | 1997-06-18 |
| JPH0780780B2 (ja) | 1995-08-30 |
| AU654938B2 (en) | 1994-12-01 |
| EP0494264A1 (fr) | 1992-07-15 |
| DK0494264T3 (da) | 1998-01-26 |
| FI921353A (fi) | 1992-03-27 |
| EP0775742A2 (fr) | 1997-05-28 |
| JPH05503076A (ja) | 1993-05-27 |
| ATE154514T1 (de) | 1997-07-15 |
| WO1991004748A1 (fr) | 1991-04-18 |
| EP0775742A3 (fr) | 1998-01-14 |
| CA2065860A1 (fr) | 1991-03-30 |
| DE69030956D1 (de) | 1997-07-24 |
| DE69030956T2 (de) | 1998-01-15 |
| CA2065860C (fr) | 2001-03-27 |
| AU6612590A (en) | 1991-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI921353A (fi) | Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris. | |
| IT8223077A0 (it) | Procedimento e apparecchio per la stimolazione di processi biologici correlati all'attivita' cellulare. | |
| IT8619684A0 (it) | Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali. | |
| DE3853236D1 (de) | Apparat und Methode zur Überwachung des Türantriebes und der Fahrt eines Aufzuges. | |
| DE3778677D1 (de) | Einrichtung und verfahren zur bildsubstrahierung mit verminderung des bewegungsartefakts. | |
| BR9007938A (pt) | Metodo e aparelho o tratamento de glaucoma | |
| Gray et al. | Response of Pacinian corpuscles in the cat's toe | |
| ES2062241T3 (es) | Metodo de purificacion de la albumina serica humana. | |
| NO874522D0 (no) | Fremgangsmaate og apparat for utvinning av soelv fra brukte, sure behandlingsfluida. | |
| NO922573L (no) | Fremgangsmaate for aa paavise ben- og andre bindevevsforstyrrelser hos mennesker og dyr | |
| ES510923A0 (es) | Procedimiento y su correspondiente aparato para el adormeci-miento de animales de matanza. | |
| CA2074166A1 (fr) | Methode de traitement de maladies intestinales | |
| NO870277D0 (no) | Apparat for agning av fiskekroker. | |
| NO882373L (no) | Fremgangsmaate for silicopyrohydrolysebehandling av bruktehall-heroult-elektrolysetanker. | |
| DE3877749D1 (de) | Verfahren und vorrichtung zum kontrastausgleich von roentgenbildern. | |
| IT1241814B (it) | Sistema ad alta sensibilita' per angiografia retinica, coroideale e simili | |
| Barbolin | Investigation of the fragility of the vessel walls in irradiated dogs by a modified cup test | |
| Eng et al. | Evidence of Sensory Conflict and Recovery in Carp Exposed to Prolonged Weightlessness | |
| IT8944004A0 (it) | Procedimento per l'impianto di trattamento totale dei fumi provenienti da processi di combustione | |
| DE3764322D1 (de) | Vorrichtung zur abstuetzung des rahmens bzw. aufbau eines fahrzeuges. | |
| FR2644054B1 (fr) | Procede et dispositif pour etablir la relation pression-diametre d'une artere par des mesures non invasives | |
| RU1769857C (ru) | Cпocoб диaгhoctиkи heokkлюзиbhoгo tpomбa hижheй пoлoй behы, pacпpoctpahяющeгocя c пoдbздoшho-бeдpehhoгo ceгmehta | |
| ATE55581T1 (de) | Vorrichtung zur abstuetzung des rahmens bzw. aufbau eines fahrzeuges. | |
| IT8703385A0 (it) | Sistema di selezione dei difetti delle pelli di animali grezze o semiconciate | |
| RO66309A2 (fr) | Methode de traitement des fractures osseuses et dispositif d'application de la methode |